This case focuses on the 2001 negotiations between Mytex pharmaceuticals and the U.S. Food and Drug Administration (FDA). Outcome of the negotiations will determine the new label for the blockbuster drug for arthritis Mytex, Flaxil. Negotiations rather qualitative and different from the typical price negotiations with which students are familiar. However, at stake was $ 500 million in sales Flaxil and security of millions of patients. (B) case is the perspectives of the patient and her doctor, as they believe that the new information about the risks Flaxil author. "Hide
by Gregory Barron Source: Harvard Business School 3 pages. Publication Date: August 24, 2008. Prod. #: 909002-PDF-ENG
Related Case Solutions & Analyses:
Procter & Gamble in the 21st Century (C): Integrating Gillette
Western Technology Investment
Random House
Great Atlantic & Pacific Tea Company Inc.
Luna Pen (A)
Cultural challenges of integration: Value creation and daiichi sankyo’s indian acquisition
EDWARD JONES
PCAOB Guidance: Docket 038
Energy Gel: A New Product Introduction
Fambul Medical Practice
